Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland

被引：0
|
作者：
Michaela Barbier
Nicholas Durno
Craig Bennison
Mathias Örtli
Christian Knapp
Matthias Schwenkglenks
机构：
[1] University of Basel,Institute of Pharmaceutical Medicine (ECPM)
[2] OPEN Health,undefined
[3] AbbVie AG,undefined
来源：
The European Journal of Health Economics | 2022年 / 23卷
关键词：
Rituximab; Venetoclax; Chronic lymphocytic leukemia; Cost-effectiveness; Partitioned survival model; EVPI; 119;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：837 / 846
页数：9
相关论文
共 50 条
  • [41] Efficacy Of Bendamustine and Rituximab In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    Kataeva, Elena
    Golenkov, Anatoly
    Triphonova, Elena
    Dudina, Galina
    Mitina, Tatyana
    Lutskaya, Tatyana
    Vysotskaya, Ludmila
    Chernykh, Yulliya
    Zakharov, Sergey
    BLOOD, 2013, 122 (21)
  • [42] Comparison of Venetoclax Based Treatments for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
    Heyman, Benjamin M.
    Choi, Michael Y.
    Kipps, Thomas J.
    BLOOD, 2023, 142
  • [43] Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
    Hillmen, Peter
    Rawstron, Andy C.
    Brock, Kristian
    Munoz-Vicente, Samuel
    Yates, Francesca J.
    Bishop, Rebecca
    Boucher, Rebecca
    MacDonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John G.
    Patten, Piers E. M.
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher P.
    Forconi, Francesco
    Munir, Talha
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) : 2722 - +
  • [44] Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
    Wierda, W
    O'Brien, S
    Wen, S
    Faderl, S
    Garcia-Manero, G
    Thomas, D
    Do, KA
    Cortes, J
    Koller, C
    Beran, M
    Ferrajoli, A
    Giles, F
    Lerner, S
    Albitar, M
    Kantarjian, H
    Keating, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4070 - 4078
  • [45] Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemia
    Quinn, J. P.
    Mohamedbhai, S.
    Chipperfield, K.
    Treacy, M.
    D'Sa, S.
    Nathwani, A. C.
    LEUKEMIA & LYMPHOMA, 2008, 49 (10) : 1995 - 1998
  • [46] Cost-effectiveness of BTK inhibitors vs bendamustine and rituximab in chronic lymphocytic leukemia patients
    Nie, Jing
    Wu, Huina
    Wu, Qian
    Liu, Qi
    Liu, Lihui
    Wu, Jiyong
    FUTURE ONCOLOGY, 2023, 19 (38) : 2525 - 2536
  • [47] COST-EFFECTIVENESS OF RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN THE DUTCH SETTING
    Pompen, M.
    ten Hoor, G.
    Carr, E.
    Aultman, R.
    VALUE IN HEALTH, 2009, 12 (07) : A277 - A277
  • [48] MANAGEMENT AND CARE FOLLOWING TREATMENT WITH VENETOCLAX AND RITUXIMAB FOR PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
    Alton, Peggy
    Paradis, Heather Brumbaugh
    Brander, Danielle
    Nandam, Ruby
    Rodriguez, Katherine
    Alter, Debbie
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [49] Rive-CLL: Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    McKay, John
    Al-Juhaishi, Taha
    Lai Guanhua
    Kmieciak, Maciej
    Sabo, Roy
    Sindel, Ariel
    Yazbeck, Victor
    BLOOD, 2019, 134
  • [50] COST-EFFECTIVENESS OF TREATMENT WITH RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN ROMANIA
    Lupu, A.
    Baculea, S.
    Pana, B.
    Radu, P.
    Kalfas, C.
    Baculea, S.
    Szkultecka-Debek, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 195 - 195
12345